The goal of the Pharmacology & Experimental Therapeutics (PET) Section is to develop more effective treatments for children and young adults with cancers. Our early clinical trials target children with refractory cancers, for whom no curative treatment exists. Drugs with new and different mechanisms of action are developed in trials called phase I or phase II trials. In addition to an active early clinical trials program for children with refractory cancers, the PET Section has established a program for children and young adults who are predisposed to the development of tumors due to a genetic disorder such as neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and medullary thyroid carcinoma.
Phase I and II trials for refractory cancers including medullary thyroid carcinoma:
With questions regarding these trials, please contact Ms. Trish Whitcomb (phone: 301-496-0128, e-mail: email@example.com).
Neurofibromatosis type 1 and 2 trials:
With questions regarding these trials please contact Ms. Andy Gillespie (phone: 301-402-1848, e-mail:firstname.lastname@example.org) or Ms. Andrea Baldwin (phone 201-594-9976, e-mail: email@example.com).
Children’s Oncology Group Phase I consortium trials:
With questions regarding these trials, please contact Ms. Anne Goodwin (phone: 301-594-4762, e-mail:firstname.lastname@example.org) or Ms. Wendy Goodspeed (phone 301-594-4762, e-mail:email@example.com).
The multidisciplinary team at the National Cancer Institute consists of pediatric oncologists, nurse practitioners, research nurses, radiologists, diagnostic, surgical oncologists, radiation oncologists, medical oncologists, neurologists, geneticists, genetic counselors, pathologists, social workers, neuropsychologists, dermatologists, and other specialists
- Andrea Baldwin, CRNP
- Joanne Derdak, CRNP
- Andy Gillespie, RN
- Wendy Goodspeed, RN
- Anne Goodwin, RN
- Trish Whitcomb, RN
- Kate Tepas Wise, RN